Neumora Therapeutics announced that its Phase 3 KOASTAL-2 and -3 trials for navacaprant, a treatment for major depressive disorder, did not meet primary or key secondary endpoints, leading to discontinuation of navacaprant's development. Despite this setback, the company remains focused on advancing other promising programs targeting Alzheimer's agitation, schizophrenia, and cardiometabolic disease, with several clinical milestones expected by the end of 2026. Neumora is also reducing its workforce by 35% to save costs and has a cash runway extending into the third quarter of 2027.
More than 200 companies are actively developing over 220 drugs for glioblastoma, the most aggressive brain cancer, with 16+ drugs in late-stage trials. Key therapies include targeted treatments, immunotherapies, and metabolic modulators, reflecting a...
MLCommons announced the MLPerf Training v6.0 benchmark results, introducing two new benchmarks—DeepSeek V3 and GPT-OSS 20B—that highlight the industry's shift toward sparse computation using Mixture-of-Experts (MoE) architectures. These benchmarks te...
RootsFi has integrated Cap's stcUSD as a primary yield source on the Tempo payment network, allowing users' balances to earn native yield backed by financial guarantees. This integration combines Tempo's fast Layer 1 payment infrastructure, RootsFi's...
AppFolio has enhanced its Performance Platform with new AI-driven features across leasing, accounting, and resident operations, integrating Anthropic’s Claude AI to automate complex workflows. These updates include automated invoice processing, multi...
Metallium Limited has successfully operated three Flash Joule Heating units simultaneously at its Texas facility, marking a key milestone in scaling its proprietary technology. The operation achieved 83% availability and nearly 100% utilization, exce...
